Xue Teng
Harbin, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
Cost-effectiveness analysis of dostarlimab plus chemotherapy versus pembrolizumab plus chemotherapy as first-line treatment of metastatic non-squamous non-small cell lung cancer.
Journal: Journal of chemotherapy (Florence, Italy)
Published: June 28, 2025
Cost-effectiveness analysis of adagrasib with or without cetuximab in the treatment of colorectal cancer patients with mutated KRAS G12C.
Journal: Expert review of pharmacoeconomics & outcomes research
Published: June 16, 2025
Cost-effectiveness analysis of sotorasib plus panitumumab in the treatment of refractory colorectal cancer with mutated KRAS G12C in the USA.
Journal: Expert review of pharmacoeconomics & outcomes research
Published: June 16, 2025
Cost-effectiveness analysis of FOLFOXIRI plus bevacizumab versus mFOLFOX6 plus bevacizumab as first-line treatment of metastatic colorectal cancer.
Journal: Expert review of pharmacoeconomics & outcomes research
Published: May 21, 2025
Integrating bioinformatics and machine learning to discover sumoylation associated signatures in sepsis.
Journal: Scientific reports
Published: October 09, 2024
A comparison of panitumumab and cetuximab in the treatment of KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis.
Journal: Immunopharmacology and immunotoxicology
Published: August 11, 2022
The role of emodin on cisplatin resistance reversal of lung adenocarcinoma A549/DDP cell.
Journal: Anti-cancer drugs
Published: May 18, 2021
[Retracted] PADI4‑mediated epithelial‑mesenchymal transition in lung cancer cells.
Journal: Molecular medicine reports
Published: June 05, 2018
PADI4‑mediated epithelial‑mesenchymal transition in lung cancer cells.
Journal: Molecular medicine reports
Published: June 05, 2018
Showing 1-10 of 10
Last Updated: 09/26/2026